Jiangsu Nhwa Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Nhwa Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical company focused on central nervous system drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New depression drug NH102 begins human safety testing
Symptom relief CompletedThis early-stage trial tested the safety and tolerability of a new drug called NH102 in 40 healthy adults. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The study is complete, but it does not yet test if NH10…
Phase 1 • Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New depression drug shows promise in early trial
Symptom relief CompletedThis study tested a new medicine, NH102, to see if it helps with major depression. 243 adults with depression took part. The goal was to check if NH102 reduces symptoms like sad mood and sleep problems better than a placebo or an existing drug. The results will help design larger…
Phase 2 • Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Alzheimer's drug candidate NH280105 passes first safety check in healthy people
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug called NH280105 in 32 healthy adults. Researchers gave single and multiple doses to see if it causes side effects and how the body processes it. This is a first step to see if the drug is safe enough to test in people with Al…
Phase 1 • Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC